GLP-1 receptor agonists (semaglutide, tirzepatide, and the next generation behind them) shift glucose, lipids, inflammation, kidney function, and liver enzymes
With pervasive stress and the prevalence of nutritionally deficient fast-food options around every corner, losing weight and keeping it off is challenging in today's day and age

Saxenda (Liraglutide) FDA approval: 2014 for chronic weight management Indicated population: Adults with BMI 30, OR Adults with BMI 27 with at least one weight-related condition Also available as: Victoza (lower dose, approved for Type 2 diabetes) Ozempic (Semaglutide) FDA approval: 2017 for Type 2 diabetes Indicated population: Adults with Type 2 diabetes as adjunct to diet and exercise Not approved for: Weight loss (though commonly prescribed off-label) Wegovy (Semaglutide) FDA approval: 2021 for chronic weight management Indicated population: Adults with BMI 30, OR Adults with BMI 27 with at least one weight-related condition Adolescents aged 12+ with obesity Same medication as Ozempic: Different dosing and FDA indication Practical Implications The regulatory distinctions matter for: Insurance coverage: Medications are often covered only for their approved indications
Ozempic vs Insulin: Which Is More Effective for Weight Loss
Oral administration subjects the peptide to gastric degradation, which is why most peptides cannot be taken orally
Even as caloric intake decreases, it's important to meet your daily protein needs